Team

Eric Yu
Partner>

Focus on Healthcare (Biotech, Medical Devices & Diagnostics, Digital Health)

Dr. Eric Yu is a Partner of Matrix China. He joined Matrix China in 2014. Dr. Yu‘s investment cases at Matrix China include: Peijia , RemeGen, Chemclin, InventisBio, Biostar, Genecast, Ambrx, Advaccine, Scivita Medcial, etc.

Prior to joining Matrix China, Dr. Yu was responsible for healthcare investments at Fidelity Growth Partners China from 2012 to 2014. From 2009 to 2012, Dr. Yu served as the Deputy General Manager of the Northeast Office of Shenzhen Capital Group, where he helped found the branch and was responsible for developing investment opportunities in the region. Prior to this, Dr. Yu worked in the Global Healthcare Department of UBS Investment Bank and McKinsey's New York office. Dr. Yu has also conducted research in bioinformatics and structured drug design at Yale University and Columbia University, respectively.

In 2021, Dr. Yu was rated by 36Kr as China's TOP20 Investors in Healthcare.

  • Introduction

    Partner
    Shanghai office
    +86-21-6162-0600
    This email address is being protected from spambots. You need JavaScript enabled to view it.

  • Select Investments

    Bota Bio
    Advaccine
    SCIVITA MEDCIAL
    Triastek
    Chemclin
    Peijia
    Huahui Health
    ONE Chip
    NovoCodex Bio
    InventisBio
    Up Clinics.
    Genecast

  • Areas of Interest

    Healthcare

  • Experience

    Fidelity Growth Partners China, VP
    Northeastern office of Shenzhen Capital Group, Deputy General Manager
    UBS Investment Bank
    McKinsey

  • Education

    Ph.D. in computational Chemistry, Columbia University
    MBA in Tuck School of Business at Dartmouth, Columbia
    B.S in chemistry, Peking University